6 assets in Osteopetrosis

Therapeutic assets addressing Osteopetrosis, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Alemtuzumab Osteopetrosis	Masonic Cancer Center, University of Minnesota	P2/3	BB (67)
Fludarabine Osteopetrosis	Masonic Cancer Center, University of Minnesota	P2/3	BB (67)
Busulfanum Osteopetrosis	Masonic Cancer Center, University of Minnesota	P2/3	BB (65)
Cald Hr-D Osteopetrosis	Masonic Cancer Center, University of Minnesota	P2	CCC (53)
Bpx-501 T Cells Osteopetrosis	Bellicum Pharmaceuticals	P1/2	CC (47)
Rimiducid Osteopetrosis	Bellicum Pharmaceuticals	P1/2	CC (46)